MyMD-1 is under clinical development by MyMD Pharmaceuticals and currently in Phase II for Sarcopenia. According to GlobalData, Phase II drugs for Sarcopenia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MyMD-1 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MyMD-1 overview

MyMD-1 (Isomyosamine) is under development for the treatment of multiple sclerosis, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, immune mediated, sarcopenia, frailty, chronic inflammation, rheumatoid arthritis, type 2 diabetes, inflammatory bowel disease, delay aging, cytokine storm and traumatic optic neuropathy (TON). It is a synthetic derivative of tobacco alkaloids, that is administered through oral route as capsule and tablet.

It was also under development for the treatment of depression.

MyMD Pharmaceuticals overview

MyMD Pharmaceuticals, Inc (MyMD), is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. ABI products include BreathScan alcohol detectors, CHUBE, METRON, PIFA PLUSS PF4, tri-cholesterol, PIFA chlamydia, PIFA dengue fever, PIFA malaria, PIFA syphilis, PIFA heparin, and breath ketone. The company provides testing platform technologies, which include micro particle catalyzed biosensor, particle immune-filtration assay, rapid enzymatic assay, rapid blood cell separation, and synthetic macrocycle complex. The company serves medical clinicians, individuals, corporations, and law enforcement agencies, health professionals. MyMD is headquartered in Baltimore, Maryland, in the US.

For a complete picture of MyMD-1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.